GYRE- Gyre Therapeutics, Inc.
Classified under Biotechnology (Health Care sector), GYRE's insider flows are most useful compared with peers in the same group.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 2.57M | $17.11M | - | |
| 10% | 458.1K | $3.06M | - | |
| Dir | 52.0K | $346.8K | - | |
| CFO | 50.0K | $333.5K | - | |
| Dir | 40.0K | $266.8K | - |
Activity
Buys and sells only
Transactions
10 filings · page 5
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2024 | Usman Nassim67 | Director | Sale+OE | 20,000 | $14.13 | $282,577.00 | -66.4% | +2.7% | -32.6% | |
| Apr 1, 2024 | Usman Nassim67 | Director | Sale+OE | 20,000 | $16.15 | $323,000.00 | -92.4% | -24.0% | -59.6% | |
| Mar 15, 2024 | Usman Nassim67 | Director | Sale+OE | 20,000 | $17.26 | $345,200.00 | -92.4% | -34.1% | -27.7% | |
| Aug 9, 2022 | Usman Nassim67 | President &CEO | Buy | 3,250 | $0.47 | $1,527.50 | +15.3% | +13.8% | +14.8% | |
| Aug 9, 2022 | Miller Seline E. | SVP Finance; Interim CFO &Pao | Buy | 3,250 | $0.47 | $1,527.50 | +100.0% | +13.8% | +14.8% | |
| Aug 9, 2022 | Blouse Grant E.51 | Chief Scientific Officer | Buy | 3,250 | $0.47 | $1,527.50 | +52.7% | +13.8% | +14.8% | |
| Feb 9, 2022 | Usman Nassim67 | President &CEO | Buy | 3,250 | $0.46 | $1,495.00 | +18.0% | -33.9% | +192.0% | |
| Feb 9, 2022 | Miller Seline E. | SVP Finance; Interim CFO &Pao | Buy | 3,250 | $0.46 | $1,495.00 | New | -33.9% | +192.0% | |
| Feb 9, 2022 | Blouse Grant E.51 | Chief Scientific Officer | Buy | 3,250 | $0.46 | $1,495.00 | +111.4% | -33.9% | +192.0% | |
| Aug 9, 2021 | Usman Nassim67 | President &CEO | Buy | 867 | $3.62 | $3,138.54 | +5.0% | -26.5% | -57.0% |